,11 According to the authors, in the early phase of an AMI, several mechanisms may not be amenable to modification with SGLT-2 inhibition, including cardiac causes, such as stent thrombosis and recurrent myocardial infarction, and noncardiac causes during the first 30 days after AMI, contributing to mortality.9 The gene discussed is SLC5A2; the disease is myocardial infarction.